Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Mark Litzow

Mark Litzow


Academic History

Mark Litzow, MD, is a Professor of Medicine and the Head of the Acute Leukemia Group at Mayo Clinic, Rochester, MN.

After obtaining an MD from the University of Chicago Pritzker School of Medicine, Chicago, IL, Dr Litzow underwent specialized training in Hematology/Oncology and General Internal Medicine. He has also been involved in a research fellowship as Mayo Foundation Scholar at the Fred Hutchinson Cancer Research Center, Seattle, WA.

Dr Litzow currently serves as the Chair of the Leukemia Committee for the Eastern Cooperative Oncology Group and the American College of Radiology Imaging Network (ECOG-ACRIN) and has actively contributed to the development of large Phase II and Phase III clinical trials for over two decades. His extensive involvement includes a longstanding and active membership in the Acute Leukemia Committee for the Center for International Blood and Marrow Transplant Research (CIBMTR). Additionally, Dr Litzow was the Chair of the Myeloid Disease Oriented Group at Mayo Clinic from 2002 to 2016.

Speaking on acute leukemia, immunotherapy, and BCR::ABL1 as a marker of MRD

Dr Litzow specializes in treating acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), aplastic anemia, myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs). His research focuses on the treatment of these hematologic malignancies with blood and marrow transplantation, chemotherapy, and novel immunologic therapies. Dr Litzow played a pivotal role in the development of the ECOG-ACRIN E1910 trial (NCT02003222), which investigated the efficacy of blinatumomab as a consolidation treatment for ALL. Additionally, Dr Litzow explores the value of BCR::ABL1 as a marker of measurable residual disease (MRD) to assess treatment responses.